Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

How the latest AI executive order might impact drug development in the U.S.

By Brian Buntz | October 30, 2023

White House

Image courtesy of Wikipedia

The White House has released an executive order that contains what it hails as “the most sweeping actions ever taken to protect Americans from the potential risks of AI systems.” Relevant to drug development, a fact sheet on the order describes its aim to help further “the responsible use of AI in healthcare and the development of affordable and life-saving drugs.” Additionally, Biden highlighted AI’s potential to help “develop cancer drugs that will work better and cost less.”

President Biden remarked in a speech on the announcement that AI has the potential to induce more technological change in the next five to ten years than we have seen in the last fifty years. He said the technology would be instrumental in “exploring the universe, fighting climate change, and in cancer.” In particular, the AI order also is designed to protect against the risks of using AI to synthesize new chemicals and biological materials, and will require government agencies funding life science projects to follow these standards as a prerequisite.

Other provisions of the order that could affect drug developers include its potential to affect AI-assisted clinical trials. The order could require drug developers to ensure that their algorithms do not exacerbate discrimination in clinical trials or patient interactions. Drug developers processing patient data or other sensitive information will need to prioritize privacy-preserving techniques in their AI systems.

In addition, the executive order directs the Department of Health and Human Services to create a program to evaluate potentially harmful AI-related health care practices. This provision could potentially involve drug developers using AI. 

Measures that could codify responsible AI

The presidential directive also has a provision intended to gauge the labor market impact of AI systems, which could impact pharma companies with aggressive plans to integrate AI systems into their drug development processes. 

Biden has repeatedly called for America to help drive “responsible AI innovation.” To help support the burgeoning AI industry in the U.S., the executive order also aims to promote innovation and competition in the AI ecosystem, offering access to grants for AI research in health care and other areas. Other countries, most notably China, have made significant investments in the development of AI systems in recent years. 

The executive order calls for a whole-of-government approach to regulating AI, aiming to set standards and rules around the technology. In that vein, the presidential directive aims to foster collaboration with international stakeholders to refine AI standards. The potential standards from this request could impact drug developers operating in global markets. 

In addition, the executive order asks each federal agency to create the position of a chief AI officer. 

The move follows voluntary commitments Biden has secured from prominent AI companies. 

Mixed assessments of the AI executive order

Initial assessments of the executive order have been mixed. The online trade association referred to the order as “a red tape AI” wishlist, arguing that it puts “the future of American innovation and global technological dominance at risk.”  Texas Senator Ted Cruz said the new rules would stymie innovation. Conversely, IBM noted in a statement that the directive ensures that “AI used by the United States government will be responsible AI.”  Similarly, Maya Wiley, president and CEO of The Leadership Conference on Civil and Human Rights, stated: “The White House Executive Order on Artificial Intelligence is an important next step to get federal agencies better prepared to use its decision-making power in a way that increases protections, rather than letting AI run unchecked.”

It remains to be seen how well federal authorities can enforce the executive order’s provisions, as its ability to do so will hinge on the willingness of Congress to provide the necessary funding for it.

Earlier this year, Biden sought to reboot the Cancer Moonshot project.

Although the pharma industry has tended to prefer BIden’s handling of the pandemic to Trump’s, the industry has resisted the Inflation Reduction Act, signed into law in August 2022. The law called for substantial changes in the U.S. pharmaceuticals market, including measures to prevent increases in drug prices from surpassing inflation and the introduction of price negotiations for certain  prescription Medicare drugs.


Filed Under: clinical trials, Data science, Legal precedents and interpretations, machine learning and AI
Tagged With: AI in healthcare, artificial intelligence, biopharma, Biotech Innovation, drug development, executive order, pharmaceutical industry
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Accelerating science with AI-enhanced cryo-EM workflows
Abstract neural network
Inside IQVIA’s quest to build a multi-agent AI ‘dream team’ to transform clinical trials
Recursion-MIT AI screens thousands of molecules before a single FEP run completes
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE